Definium Therapeutics reports positive Phase 3 results and financial updates.
Definium Therapeutics (DFTX) filed an 8-K with the SEC on Nov 9, 2026, 4:10 pm ET. Source: the filing on SEC EDGAR.
Item 2.02 Reports results
- Form
- 8-K
- Filed
- Importance
- Major
- Accession
- 0001193125-26-453595
- Received FDA Breakthrough Therapy Designation for DT120 ODT in MDD.
- DT120 ODT met primary endpoints in two Phase 3 GAD studies.
- Approximately $1.05 billion in cash, cash equivalents, and investments as of September 30, 2026.
- DT402 showed positive initial results in a Phase 2a trial for ASD.
Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.